Latest News
Drug updated on 5/17/2024
Dosage Form | Injection (intravenous; 300 mg/30 mL [10 mg/mL], 300 mg/3 mL [100 mg/mL], 1,100 mg/11 mL [100 mg/mL]); Injection (subcutaneous; 245 mg/3.5 mL [70 mg/mL]) |
Drug Class | Complement inhibitors |
Ongoing and Completed Studies | ClinicalTrials.gov |
Indication
- Indicated for the treatment of adult and pediatric patients one month of age and older with paroxysmal nocturnal hemoglobinuria (PNH).
- Indicated for the treatment of adult and pediatric patients one month of age and older with atypical hemolytic uremic syndrome (aHUS) to inhibit complement-mediated thrombotic microangiopathy (TMA).
- Indicated for the treatment of adult patients with generalized myasthenia gravis (gMG) who are anti-acetylcholine receptor (AChR) antibody positive.
- Indicated for the treatment of adult patients with neuromyelitis optica spectrum disorder (NMOSD) who are anti-aquaporin-4 (AQP4) antibody positive.
Summary
- Ravulizumab-cwvz (Ultomiris) is recommended for adult and pediatric patients one month of age and older with paroxysmal nocturnal hemoglobinuria (PNH), atypical hemolytic uremic syndrome (aHUS), generalized myasthenia gravis (gMG) who are anti-acetylcholine receptor antibody positive, and neuromyelitis optica spectrum disorder in adults who are anti-aquaporin-4 antibody positive.
- The analysis on Ultomiris involved six systematic reviews/meta-analyses, comparing Ultomiris with other treatments focusing on safety, efficacy, and applicability among different population types, including subgroups with the indicated conditions such as NMOSD, aHUS, PNH, and gMG.
- In the case of NMOSD patients seropositive for anti-AQP4 antibodies, Ultomiris significantly reduced the rate of the first adjudicated relapse while enhancing disability levels and quality of life. Its safety profile was comparable to placebo, indicating good tolerability.
- In the treatment of aHUS, Ultomiris and Eculizumab were equally effective. Both treatments play crucial roles in inhibiting the complement cascade integral to the pathogenesis of aHUS, with similar safety profiles. However, there was a preference for Ultomiris due to its lower financial impact and less frequent dosing requirements.
- For managing PNH compared to Eculizumab or the C3 inhibitor pegcetacoplan, Ultomiris showed substantial efficacy by reducing hemolysis, as measured by LDH levels, increasing hemoglobin levels, and preventing the need for transfusions, thereby further improving the quality of life and demonstrating comparable safety over various treatment durations.
- Ultomiris did not show a significant difference in effectiveness against gMG when compared with FcRn treatments like efgartigimod and rozanolixizumab in improving Myasthenia Gravis-Activities of Daily Living scale (MG-ADL) scores. However, FcRn treatments had a greater short-term effect on the Quantitative Myasthenia Gravis scale (QMG) scores.
Product Monograph / Prescribing Information
Document Title | Year | Source |
---|---|---|
Ultomiris (ravulizumab) Prescribing Information. | 2024 | Alexion Pharmaceuticals, Inc., Boston, MA |
Systematic Reviews / Meta-Analyses
Document Title | Year | Source |
---|---|---|
Role of C5 inhibitors in neuromyelitis optica spectrum disorders with seropositive anti-aquaporin-4 antibody: a systematic review and meta-analysis. | 2024 | Multiple Sclerosis and Related Disorders |
Eculizumab versus ravulizumab for the treatment of atypical hemolytic uremic syndrome: a systematic review. | 2023 | Cureus |
Complement inhibition in paroxysmal nocturnal hemoglobinuria (PNH): a systematic review and expert opinion from central Europe on special patient populations. | 2023 | Advances in Therapy |
Efficacy of innovative therapies in myasthenia gravis: a systematic review, meta-analysis and network meta-analysis. | 2023 | European Journal of Neurology |
Efficacy of complement inhibitors for patients with paroxysmal nocturnal hemoglobinuria: a systematic review and meta-analysis. | 2023 | Therapeutic Advances in Hematology |
Interventions for atypical haemolytic uraemic syndrome. | 2021 | The Cochrane Database of Systematic Reviews |
Clinical Practice Guidelines
Document Title | Year | Source |
---|---|---|
A critical appraisal of clinical practice guidelines for pharmacological treatments of paroxysmal nocturnal hemoglobinuria. | 2023 | Journal of Advances in Biology & Biotechnology |